A few very interesting suitors. I am a little surprised, but now at $70 billion this company is much more attainable. They are also looking at strategic acquisitions.
If GILD has blowout earnings (as some analysts are predicting) then the entire sector will be up BIG and BIIB should easily pass $325 tomorrow!
Makes a lot of sense for Allergan CEO to be "shopping" given the $35 billion they will be getting. I think Pfizer may also be doing some DD on Biogen. Lets see if the Biogen board of directors approve a "purchase" first of someone like an ISIS or BioMarin. Will be an interesting next 3-5 months for sure! In the meantime, BIIB is probably going atleast 10-15% higher from here until some news is announced.
Sentiment: Strong Buy
Nice to see the Chairman buying $3 milllion dollars worth of shares using his own money!
Sentiment: Strong Buy
....Biogen (BIIB) Chairman Stelios Papadopoulos appears to be among those betting that the 22% drop in BIIB's shares last Friday was overdone. Papadopoulos today pays about $3.05M to acquire 10,000 BIIB shares at around $305, according to an SEC filing. A number of analysts also chimed in today to support BIIB, especially at its current levels. Bernstein upgrades the stock to market-outperform from market-perform previously, though it also lowered its target price to $385 from $436. Deutsche Bank calls the "current stock move as overreaction" and says it sees "potential upside to" BIIB's significantly reduced 2015 guidance. BIIB closes up 3.1% to $309.43. ..
Sentiment: Strong Buy
So what you are saying is that Biogens pipeline is worth 0 and the company whose fair value with no pipeline
is worth at least 300 a share is $75 over valued ? l.o.l you are a bozo. There may be a lot of overvalued
biotechs but BIIB is certainly not one of them. With there buybacks also it makes the stock worth more than
what it is now. go ahead and short it to 225 and best of luck. l.o.l
every hedge fund is knee deep in biotech shares. guess what folks? most biotech companies fail. the bursting of the biotech bubble will be one for the record books. i see 100+ of them going to $0! and biogen will go to $225!
When it popped 20+ this morning...I sold (5) august 21st 350 calls for $1900. I left 3 of them naked as I am still holding 200 shares long. Trying to offset some losses.
Biogen probably won't agree to be acquired for less than $450 per share (approx. $100B), so any potential suitor must be confident that the value of the pipeline (i.e. Aducanumab) far outweighs the slumping sales of Tecfidera and Tysabri. BIIB management made it very clear that sales of their main MS drugs will remain flat for the remainder of 2015.
I personally hope BIIB does get bought out, if for nothing else to get rid of current management. BIIB lost 22% in one day purely because of management's horrible job of setting realistic expectations with Wall St. Instead of a soft landing we got a hard crash. Biogen's assets would be in much better hands with AGN, but I'm not sure if BIIB is AGN's primary target.
BIIB may have to dig itself out of this hole all on its own. If that's the case then I hope they quickly move to make an acquisition. Acorda Therapeutics is a good match, as they already have a licensing agreement with BIIB. BioMarin or ISIS Pharma would also be good acquisition targets. BIIB has room on the balance sheet to make several purchases.
A lot of people are saying this. I am an AVXL shareholder myself and up just a hare under 2x. Yes BIIB should buy them, but that would have no impact on you as a BIIB shareholder right now as it's too small and too speculative. I know you're reading about the nice phase IIa results but assuming you're knowledgeable in biotech you still know what a long shot AVXL is for AD.
That's to be determined. It will not be a new drug approval. But could be M&A, expense reductions, etc. Even the talk of M&A and/or perception that the company is in play (or playing) is a catalyst.
BIIB is used to thinking of themselves as being in the $100B club but oops - they are now at $70B!
In contrast, AGN ($121B) just landed another $40B today and they LOVE neurology. PFE ($210B) and MRK ($162B) could use pipeline and could handle neurology. While GILD ($162B) and CELG ($118B) have the caps to take on BIIB, neurology is not a fit for them.
BIIB will have to take on strategic acquisitions soon - "eat or be eaten".
BIIB should buy AVXL a small 75mil market cap company whose Alzheimer's drug just showed 4x that's a 400% improvement over the standard of care( aricept) and that's with one week on one week off dosing!! Buy of the century!!! Load up on Avxl still under a dollar could EASILY be at 5$ by Christmas! Do your own DD as always. You can get around 400 shares of Avxl for every one share of biib. Load up your trucks and trailers ladies